Medical Oncology & Systemic Cancer Therapeutics
A comprehensive clinical overview of systemic antineoplastic therapies, immune checkpoint inhibitors, targeted kinase inhibitors, and antibody-drug conjugates.
Overview
Medical oncology is the medical specialty dedicated to the systemic pharmacological management of cancer. Medical oncologists direct overall multimodal cancer care, integrating genomic sequencing, pharmacokinetic profiling, and patient performance status to deliver cytotoxic chemotherapy, precision targeted therapies, immunotherapies, hormonal modulators, and cellular therapies.
Major Systemic Treatment Modalities
| Modality |
Mechanism of Action |
Clinical Role |
Representative Agents |
| Cytotoxic Chemotherapy |
Inhibits cell division via DNA cross-linking, alkylation, or mitotic spindle disruption. |
Curative, neoadjuvant tumor downstaging, adjuvant recurrence prevention, palliative |
Cisplatin, Carboplatin, Paclitaxel, Doxorubicin, 5-Fluorouracil (5-FU), Gemcitabine |
| Targeted Kinase & Small Molecule Therapy |
Blocks specific mutant intracellular enzymatic active sites or oncogenic receptor signaling pathways. |
Precision therapy for tumors harboring actionable genomic alterations |
Osimertinib (EGFR), Dabrafenib (BRAF), Sotorasib (KRAS G12C), Imatinib (BCR-ABL) |
| Immune Checkpoint Blockade |
Monoclonal antibodies blocking PD-1/PD-L1 or CTLA-4 inhibitory pathways, restoring T-cell anti-tumor cytotoxicity. |
Durable immunotherapeutic responses across solid tumors and hematological cancers |
Pembrolizumab, Nivolumab, Ipilimumab, Atezolizumab, Durvalumab |
| Antibody-Drug Conjugates (ADCs) |
Target-specific monoclonal antibodies linked to potent cytotoxic payloads (topoisomerase inhibitors, tubulin toxins). |
Targeted intracellular delivery with minimal off-target systemic toxicity |
Trastuzumab deruxtecan (T-DXd), Sacituzumab govitecan, Enfortumab vedotin |
| Endocrine & Hormone Therapy |
Suppresses hormonal production or blocks nuclear hormone receptors driving proliferation. |
Adjuvant and metastatic management of hormone-sensitive malignancies |
Tamoxifen, Letrozole, Anastrozole, Enzalutamide, Abiraterone acetate |
Treatment Timing & Strategic Objectives
- Neoadjuvant Therapy: Administered prior to definitive surgery or radiation to downstage locally advanced tumors and assess in-vivo pathological response.
- Adjuvant Therapy: Administered following complete surgical resection to eradicate occult micrometastatic disease and reduce distant recurrence risk.
- Concurrent Chemo-Radiotherapy: Chemotherapy agents acting as radiosensitizers to enhance radiation-induced cellular destruction.
- Maintenance Therapy: Well-tolerated continuous systemic regimens extending progression-free survival following successful induction chemotherapy.
Systemic oncological therapies are individualized based on tumor histology, molecular profiling, biomarker status, and organ function, supported by proactive antiemetic, hematological, and supportive care protocols.
